Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Teams with Horizon on Oncology Cell Lines

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced that it is incorporating Horizon Discovery’s oncology cell lines into its offerings from Caliper Discovery Alliances and Services.
 
According to Hopkinton, Mass.-based Caliper, the deal provides CDAS with unique, genetically defined, and isogenic human cancer cell lines that will enable researchers to better identify and characterize personalized drugs targeted at specific subsets of patients.
 
The firm said that the cell lines provide scientists with a better understanding of the mechanism of action of compounds, directly identify patient-relevant compounds from large compound libraries, re-profile existing drugs for new indications, and identify potential side effects early in the drug development process.
 
Caliper expects the cell lines to “enhance the success rate and reduce the cost of discovering targeted monotherapy or combination therapies that better treat disease with fewer adverse events,” David Manyak, Caliper’s EVP of drug discovery services, said in a statement.
 
The firms did not disclose terms of the alliance.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.